Cocrystal Pharma Presentation at the reimagine Health Research Symposium Features Overview of Platform Technology and Four An...
January 21 2021 - 8:00AM
Cocrystal Pharma, Inc. (Nasdaq: COCP),
(“Cocrystal” or the “Company”), a clinical-stage biotechnology
company discovering and developing novel antiviral therapeutics
that target the replication machinery of influenza viruses, the
SARS-CoV-2 virus, hepatitis C viruses and noroviruses, provides the
following summary of today’s upcoming presentation by Cocrystal
President Sam Lee, Ph.D. at the virtual 3rd Annual reimagine Health
Research Symposium, University of Arizona College of Medicine. A
live webcast of Dr. Lee’s presentation, titled “Application of
Structure-Based Drug Design Platform Technology for Developing
Broad Spectrum, COVID-19, Influenza, and HCV Antivirals,” will be
available at 9:50 a.m. Pacific time (12:50 p.m. Eastern time) by
registering here. Dr. Lee’s presentation will be available on the
Cocrystal website here beginning Friday, January 22, 2021.
Dr. Lee will provide an overview of the
Company’s drug discovery platform technology, including its unique
ability to develop broad-spectrum antiviral therapeutics and its
advantages compared with the traditional drug discovery and
development process. He will emphasize that the technology platform
focuses on well-validated antiviral drug targets and review four
case studies on the following compounds:
- CC-31244, a pan-genotypic hepatitis
C virus (HCV) non-nucleoside inhibitor that has shown superior
activity against all known HCV drug-resistant polymerases, exhibits
a high barrier to drug resistance and has successfully completed a
Phase 2a clinical trial;
- Pan-genotypic HCV inhibitors bind
to a highly conserved CBP-1 binding pocket of HCV NS3 helicase and
inhibit the viral replication;
- CC-42344, a broad-spectrum pandemic
and seasonal influenza A inhibitor that binds to the highly
conserved m7GTP binding pocket of PB2, has exhibited a favorable
preclinical safety profile and pharmacokinetic properties, and is
expected to enter into Phase 1 clinical trials in 2021; and
- SARS-CoV-2 direct-acting antiviral
3CL (or main) protease inhibitor is in preclinical development for
the treatment of COVID-19.
“The traditional route for drug discovery and
development requires target identification and validation, making
for a slow process with a high rate of attrition,” said Dr. Lee.
“Cocrystal’s unique platform technology has the ability to provide
3D structures of inhibitor protein complexes at near-atomic
resolution, allowing us to identify novel drug-binding pockets
essential for viral replication and transcription. We then design
and develop broad-spectrum viral inhibitors that have the added
benefit of providing a high-barrier to drug resistance.
“We are delighted to have the opportunity to
showcase the potential of our structure-based drug discovery
platform technology in developing a diverse pipeline of antiviral
compounds that could have meaningful impact on multiple high-value
indications,” he added.
About the reimagine Health Research
Symposium
The 3rd Annual reimagine Health Research
Symposium will focus on current topics in the areas of intervention
and prevention of important diseases that are impacting humankind.
It will emphasize approaches for a variety of diseases and
crises—including COVID-19, cardiovascular disease, cancer, opioid
addiction and the need to develop novel antibiotics. Attendees will
learn from and engage with leading experts who will present and
discuss contemporary treatment and prevention strategies in the
areas of drug discovery, vaccine development, addiction management
and the use of artificial intelligence, as well as the ethical and
social factors contributing to these approaches. The reimagine
Health Research Symposium is co-sponsored and planned by the
Arizona Biomedical Research Centre, the University of Arizona
College of Medicine – Phoenix Research Office and the Flinn
Foundation. More information about the symposium is available
here.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of influenza
viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses
and noroviruses. Cocrystal employs unique structure-based
technologies and Nobel Prize-winning expertise to create first- and
best-in-class antiviral drugs. For further information about
Cocrystal, please visit www.cocrystalpharma.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including our beliefs regarding the potential
of our structure-based drug discovery platform technology. The
words "believe," "may," "estimate," "continue," "anticipate,"
"intend," "should," "plan," "could," "target," "potential," "is
likely," "will," "expect" and similar expressions, as they relate
to us, are intended to identify forward-looking statements. We have
based these forward-looking statements largely on our current
expectations and projections about future events. Some or all of
the events anticipated by these forward-looking statements may not
occur. Important factors that could cause actual results to differ
from those in the forward-looking statements include, but are not
limited to, the results of preclinical and clinical studies.
Further information on our risk factors is contained in our filings
with the SEC, including our Annual Report on Form 10-K for the year
ended December 31, 2019, as updated and supplemented by the
Quarterly Reports on Form 10-Q for the quarters ended June 30, 2020
and September 30, 2020, and the Prospectus Supplement dated August
26, 2020. Any forward-looking statement made by us herein speaks
only as of the date on which it is made. Factors or events that
could cause our actual results to differ may emerge from time to
time, and it is not possible for us to predict all of them. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by law.
Investor Contact:LHA Investor RelationsJody
Cain310-691-7100jcain@lhai.com
# # #
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Sep 2023 to Sep 2024